Association Between Sublingual Buprenorphine-Naloxone Exposure and Dental Disease

This study examines the association of sublingual buprenorphine/naloxone and dental adverse events using the IQVIA health claims database.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA : the journal of the American Medical Association 2022-12, Vol.328 (22), p.2269-2271
Hauptverfasser:	Etminan, Mahyar, Rezaeianzadeh, Ramin, Kezouh, Abbas, Aminzadeh, Kevin
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Sublingual Adverse events Analgesics, Opioid - administration & dosage Analgesics, Opioid - adverse effects Analgesics, Opioid - therapeutic use Buprenorphine Buprenorphine, Naloxone Drug Combination - administration & dosage Buprenorphine, Naloxone Drug Combination - adverse effects Buprenorphine, Naloxone Drug Combination - therapeutic use Case reports Dental caries Dental disorders Drug abuse Drug addiction Humans Letter Letters Medical personnel Naloxone Narcotic Antagonists - administration & dosage Narcotic Antagonists - adverse effects Narcotic Antagonists - therapeutic use Opioid-Related Disorders - drug therapy Research Letter Stomatognathic Diseases - chemically induced Teeth
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This study examines the association of sublingual buprenorphine/naloxone and dental adverse events using the IQVIA health claims database.
ISSN:	0098-7484 1538-3598
DOI:	10.1001/jama.2022.17485